1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Celularity Inc. appointed Naveen Jain, founder and CEO of Viome Life Sciences, to its Board of Directors, with his term to start after a Rule 14f-1 information statement waiting period. Diane Parks has notified the company she will resign from the Board as of that same effective time, and the filing says her decision was not due to any disagreement with the company.
Naveen Jain was designated under board designation rights tied to the September 2026 financing disclosed in an 8-K filed September 28, 2026.
Diane Parks will resign from the Board effective at the same time Jain's term begins.
Jain has not been appointed to any Board committee initially and will receive the standard non-employee director compensation.
The company expects to announce a fifth director shortly.
Northern Trust Chief Financial Officer David W. Fox, Jr. told the company on September 28, 2026 that he plans to retire on or around March 31, 2027. The company said it will conduct a comprehensive internal and external search for his successor, and Fox is expected to keep leading Finance during the transition.
Fox informed the company on September 28, 2026 of his plan to retire, effective on or around March 31, 2027.
Fox intends to remain in his role through the end of the first quarter of 2027 to support an orderly transition.
The company plans a comprehensive internal and external search for its next Chief Financial Officer.
Fox joined Northern Trust in 2012 and previously spent more than 25 years at JPMorgan.
Talen's board named President Terry Nutt as chief executive effective January 1, 2027, succeeding Mac McFarland, who retires March 1, 2027. The same day, Talen entered $1.5 billion of accelerated share repurchase agreements, funded by selling about $1.5 billion of future PJM capacity revenues, and raised its remaining buyback authorization to $3.0 billion. For shareholders, the buyback reduces the share count, but the company says its adjusted free cash flow forecast for 2H 2026 through 2028 falls from about $4 billion to about $2.8 billion after the capacity sale.
Terry Nutt becomes CEO and joins the board on January 1, 2027; his base salary is set at $1,200,000, with a target bonus of 135% of base and a long-term incentive target of 700% of base.
Mac McFarland serves as Senior Advisor from January 1, 2027 until his retirement on March 1, 2027, and will receive $100,000 for those services.
The ASRs with Goldman Sachs & Co. LLC and Banco Santander cost $1.5 billion, with about 4.0 million shares initially received; the company expects them to be completed by the end of the first quarter of 2027 and says they would repurchase m
The capacity monetization covers PJM 2027/2028 and 2028/2029 delivery years, with Citi, at SOFR plus 200 basis points; the company targets net leverage of 3.5x by the second half of 2027.
Kevin Shannon notified Morgan Stanley Direct Lending Fund of his intention to resign as a Director, effective September 26, 2026. The filing states the resignation is not the result of any disagreement with the Company.
Kevin Shannon resigned as a Director, effective September 26, 2026.
The filing says the resignation was not due to any disagreement with the Company.
The 8-K was signed by Co-President and Chief Operating Officer Orit Mizrachi on September 29, 2026.
Crane Company's Board accepted the resignation of Lead Independent Director James L. L. Tullis under the company's director retirement policy, effective at the conclusion of the 2027 Annual Meeting of Stockholders. The filing says the departure was not due to any disagreement with the company on operations, policies, or practices, and the Board will begin searching for a successor to the Lead Independent Director role.
Board accepted Tullis's resignation at a regularly scheduled meeting on September 27, 2026
Resignation is effective at the conclusion of the 2027 Annual Meeting of Stockholders
Filing states the retirement was not the result of any disagreement with the company
Board will begin a process to identify a successor Lead Independent Director
Plains announced that Dean Liollio will become Executive Vice President and Chief Operating Officer of the general partners of PAA and PAGP effective October 2, 2026, succeeding Chris Chandler, who is resigning to pursue other interests. The filing says Chandler's departure is not due to any disagreement over company operations, policies or practices. The filing discloses Liollio's pay package, including a $625,000 base salary and a promotional phantom unit grant.
Dean Liollio, age 67, was Senior Vice President, Special Projects, from June 2024 before his appointment as EVP and COO effective October 2, 2026.
Liollio's annual base salary is $625,000, with a bonus target of 150% of base salary.
Liollio will receive a time-based promotional LTIP grant for 150,000 phantom units vesting in August 2029.
Chris Chandler gave notice on September 25, 2026 that he will resign effective October 2, 2026.
NanoViricides, Inc. extended the employment agreements of its President, Dr. Anil Diwan, and its Chief Financial Officer, Meeta Vyas, both effective July 1, 2026. The filing sets Dr. Diwan's base salary at $400,000 through June 30, 2027, and grants him 10,204 shares of Series A Preferred Stock vesting quarterly through June 30, 2027. The extensions keep the company's two senior executives in place, with the terms disclosed in the filing.
Dr. Anil Diwan extended as President through June 30, 2027, at a base salary of $400,000
Diwan granted 10,204 Series A Preferred Shares, vesting quarterly from September 30, 2026 and fully by June 30, 2027
Diwan severance if terminated without cause: six months' salary; a $2 million term life policy is maintained for him
Meeta Vyas extended as CFO for one year through June 30, 2027; company reimburses up to 50% of health insurance costs, capped at $2,500 per month
Plains All American Pipeline and Plains GP Holdings appointed Dean Liollio, a Plains senior vice president, as executive vice president and chief operating officer effective October 2, 2026. He replaces Chris Chandler, who is resigning from the company to pursue other interests, not because of any disagreement over operations, policies or practices.
Chris Chandler gave notice of his resignation on September 25, 2026, effective October 2, 2026.
Dean Liollio, age 67, was Senior Vice President, Special Projects, from June 2024 and previously led Plains Midstream Canada.
Liollio will receive a $625,000 annual base salary, a 150% bonus target and a promotional grant of 150,000 phantom units vesting in August 2029.
Verizon's Board of Directors elected Charles Phillips, Co-Founder & Managing Partner of Recognize Partners LP, as a director effective September 25, 2026. He will receive the standard non-employee director compensation described in the company's April 6, 2026 proxy statement, and he has not yet been named to a Board committee.
Charles Phillips elected as director effective September 25, 2026
Phillips is Co-Founder & Managing Partner of Recognize Partners LP
Compensation follows the Non-Employee Director Compensation program in the April 6, 2026 proxy statement
Modular Medical said directors Jeffrey Goldberg and Carmen Volkart will not stand for re-election when their current terms expire at the fiscal 2027 annual meeting of shareholders. Both said the decisions were not due to any disagreement with the company on operations, policies or practices.
Jeffrey Goldberg gave notice on September 25, 2026 that he will not seek re-election.
Carmen Volkart notified the nominating and governance committee chair on September 24, 2026 of her decision.
Both terms expire at the fiscal 2027 annual meeting of shareholders.
The filing states neither departure resulted from a disagreement with the company.
Lesaka Technologies director Dean Sparrow resigned from the board and all committees, effective September 25, 2026, and the filing states the resignation was not due to any disagreement with the company. The board appointed Carolina Lacerda and James Oates as directors effective September 28, 2026, both determined to be independent and audit committee financial experts, which adds directors with finance and audit backgrounds.
Dean Sparrow resigned as director and from all board committees, effective September 25, 2026; notice given September 23, 2026
Board appointed Carolina Lacerda and James Oates as directors effective September 28, 2026
Lacerda expected to join the Audit and Risk Committee and Capital Allocation Committee; Oates expected to join the Audit and Risk Committee
Both new directors were determined to be independent under Nasdaq and SEC rules and qualify as audit committee financial experts
Larimar Therapeutics appointed John B. Harlow, Jr. as President and Chief Operating Officer effective September 29, 2026, under an employment agreement with a $560,000 base salary and a 40% target annual bonus. He previously served as Chief Commercial Officer at Esperion Therapeutics from November 2025 to September 2026, and the filing describes a new senior operating role for the company.
Appointment effective September 29, 2026, as President and Chief Operating Officer
Base salary of $560,000 per year, a $35,000 cash signing bonus, and a target annual bonus of 40% of base salary
Inducement grants include an option on 800,000 shares and restricted stock units covering 50,000 shares, vesting over multiple years
Severance of nine months of base salary and COBRA coverage, or twelve months of salary plus target bonus and COBRA if terminated within one year after a change in control
La Rosa Holdings Corp. (the filing names this company, not Stratum Holdings Corp.) reported that director Jaime Cosculluela resigned from its Board effective September 24, 2026, citing personal reasons and no disagreement with the company. The Board appointed Marc Urbach as a director the same day, and the Board determined he is independent under Nasdaq rules, which is a routine board change with limited direct financial effect.
Jaime Cosculluela resigned from the Board effective September 24, 2026, for personal reasons, not due to any disagreement.
Marc Urbach was appointed to the Board effective September 24, 2026, and was determined to be independent under Nasdaq Rule 5605(a)(2).
Urbach receives a quarterly base fee of $12,000 and a quarterly chair fee of $3,000 under a Board of Directors Agreement (Exhibit 10.1).
Acuity Inc. increased its Board from nine to ten members and elected Nick Tzitzon as an independent director, effective September 24, 2026. Tzitzon was also appointed to the Audit and Governance Committees, which adds a new director with software and AI leadership experience to oversight roles.
Board size increased from nine to ten members; Tzitzon elected effective September 24, 2026
Tzitzon is Vice Chairman of ServiceNow, Inc. since January 2020 and leads its AI Institute
Previously Executive Vice President of SAP SE from October 2012 to January 2020
Joins Audit and Governance Committees; initial term expires at next annual meeting
Lightwave Logic's board appointed Edward Kennedy as a Class I director effective September 23, 2026, filling a seat created by expanding the board from six to seven members. Kennedy has more than 30 years of experience in telecom, networking and enterprise infrastructure, and he has not yet been assigned to any board committee, so the change adds a director without altering executive leadership.
Kennedy appointed effective September 23, 2026, as a Class I director; board expanded from six to seven members.
Previously CEO of CENX, Inc. (acquired by Ericsson in 2018) and CEO of Tollgrade Communications from 2010 to 2017.
Not yet appointed to any board committee; compensated like other non-employee directors under the proxy filed April 10, 2026.
TMC the metals company named Liam Mallon, a former President of ExxonMobil Upstream Company, as a director effective September 24, 2026, filling the seat vacated by Brendan May's resignation. The filing describes Mr. Mallon's energy background and his role as chair of the board's Sustainability and Innovation Committee, and it does not report any financial results or guidance.
Liam Mallon appointed director effective September 24, 2026, to fill the vacancy left by Brendan May's resignation
Mr. May resigned effective September 24, 2026, with no disagreement with the company on operations, policies or practices
Mr. Mallon received 25,445 RSUs on September 25, 2026, and a special one-time grant of 77,720 RSUs on September 28, 2026
Mr. Mallon was appointed chair of the Sustainability and Innovation Committee and is considered independent under Nasdaq listing standards
CareCloud's Board appointed Bonnie Boyer, currently Assistant Chief Financial Officer, as Chief Financial Officer effective October 1, 2026, succeeding Norman Roth, who has served as Interim CFO for more than two years. Mr. Roth becomes Advisor to the Chief Executive Officer. The filing also sets out Ms. Boyer's employment terms, including a $300,000 base salary and a target bonus of 30% of base salary.
Bonnie Boyer, 39, joined CareCloud on July 9, 2026, as Assistant CFO and becomes CFO effective October 1, 2026.
Base salary of $300,000 with an annual target bonus equal to 30% of base salary.
Norman Roth, Interim CFO and Corporate Controller, transitions to Advisor to the CEO effective October 1, 2026.
Severance includes six months of base salary and COBRA premiums if terminated without cause; if terminated in connection with a change of control, salary continuation for at least 24 months.
First United Corporation's board elected Steven R. Stuck, Shawn Bender, and Nina Beitzel as directors effective September 24, 2026, to serve until the 2027 annual meeting. The filing says the board expects to assign them to several board and bank committees, and it sets their compensation, which is routine for new directors.
Effective September 24, 2026, the board elected Steven R. Stuck, Shawn Bender, and Nina Beitzel as directors.
Each new director will receive a cash retainer of $8,750 and a grant of 583 fully-vested common shares for the period until the 2027 annual meeting.
Directors receive $1,000 per board meeting attended, reduced to $200 for certain special meetings, plus $500 per committee meeting.
Altimmune appointed Richard Menziuso as Vice President, Global Controller and Principal Accounting Officer, effective September 29, 2026. CFO Gregory Weaver remains in his role, so the change is limited to the company's accounting leadership.
Appointment made by the Board on September 24, 2026, effective September 29, 2026
Menziuso has 28 years of finance and accounting experience, including 12 years in public accounting
Previously Vice President, Corporate Controller at Centessa Pharmaceuticals from 2021 until its 2026 acquisition by Eli Lilly
Gregory Weaver will remain Chief Financial Officer
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.